title: [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea].
abstract: OBJECTIVE
  We investigated the five-year survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients who were treated at a single institute, and this is a follow-up study of a previous report.
  
  
  METHODS
  Nine hundred four HCC patients who were treated at the National Cancer Center Korea were enrolled and they were followed till February 2007.
  
  
  RESULTS
  The mean age of the patients was 56.0 years and 731 patients were male. Six hundred seventy-seven (74.9%) patients died and the overall 5-year survival rate (5-YSR) was 23.9%. The 5-YSRs of the patients with modified UICC stage I, II and III were 61.2%, 54.4% and 18.4%, respectively, and the median survival time was 4.3 and 3.7 months for the stage IVa and IVb patients, respectively. For the analysis of the treatment modality, surgical resection showed significantly better outcomes for the five-year survival as compared with transcatheter arterial chemoembolization (TACE) for Child-Pugh A patients with modified UICC stage I or II disease (80.1% vs 52.8%, respectively, P<.001), or stage III disease (60.7% vs 17.0%, respectively, P<.001). For patients with advanced stage IVb disease, TACE, systemic chemotherapy and radiotherapy increased the median survival period more than conservative management for the Child-Pugh class A patients. The serum alpha-fetoprotein level, portal vein tumor thrombosis, the Child-Pugh class, the tumor stage, the tumor type and symptoms were related to the prognosis.
  
  
  CONCLUSIONS
  This study presented, for the first time, the 5-YSRs of a cohort of HCC patients.
authors.affiliation: Center for Cancer Prevention and Detection, National Cancer Center, Goyang, Korea.
authors.forename: Kyung Woo
authors.initials: KW
authors.lastname: Park
authors.forename: Joong Won
authors.initials: JW
authors.lastname: Park
authors.forename: Tae Hyun
authors.initials: TH
authors.lastname: Kim
authors.forename: Jun Il
authors.initials: JI
authors.lastname: Choi
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Kim
authors.forename: Hong Suk
authors.initials: HS
authors.lastname: Park
authors.forename: Sang Jae
authors.initials: SJ
authors.lastname: Park
authors.forename: Woo Jin
authors.initials: WJ
authors.lastname: Lee
authors.forename: Hae Lim
authors.initials: HL
authors.lastname: Shin
authors.forename: Chang Min
authors.initials: CM
authors.lastname: Kim
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000401:mortality* / Q000601:surgery; D016461:Chemoembolization, Therapeutic; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007723:Korea; D008113:Liver Neoplasms / Q000209:etiology / Q000401:mortality* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D020266:Radiotherapy, Conformal; D012720:Severity of Illness Index; D015996:Survival Rate